NCT01204125 2017-03-22
SOLTI NEOPARP
Sanofi
Phase 2 Completed
Clinical Trials
5 trialsNCT00813956 2016-03-17
A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer
Sanofi
Phase 2 Completed
NCT01045304 2014-01-14
Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer
Sanofi
Phase 2 Completed
NCT00938652 2013-09-19
A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer
Sanofi
Phase 3 Completed
NCT00540358 2012-12-28
A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer
Sanofi
Phase 2 Completed